Glial progenitors as targets for transformation in Glioma

Advances in Cancer Research

Volumn 121, Issue , 2014, Pages 1-65

  Ilkanizadeh, Shirin ^a,b   Lau, Jasmine ^a,b   Huang, Miller ^a,b   Foster, Daniel J ^a,c   Wong, Robyn ^a,b   Frantz, Aaron ^a,c   Wang, Susan ^a,c   Weiss, William A ^a,b   Persson, Anders I ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; Cancer; Glioblastoma; Glioma; Neural stem cell; Oligodendrocyte progenitor cell

Indexed keywords

EPIDERMAL GROWTH FACTOR; H3F3A PROTEIN; HISTONE H3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYCOMB GROUP PROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN REGION; CARCINOGENESIS; CELL LINEAGE; CELL TRANSFORMATION; CHROMOSOME ABERRATION; DNA METHYLATION; DRUG TARGETING; ENZYME INHIBITION; FEEDBACK SYSTEM; GLIAL PRECURSOR CELL; GLIOBLASTOMA; GLIOMA; GLIOMAGENESIS; HUMAN; LIGAND BINDING; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; NEURAL STEM CELL; OLIGODENDROCYTE PROGENITOR CELL; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; PRONEURAL TO MESENCHYMAL TRANSITION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANIMAL; CELL DIFFERENTIATION; GENETICS; GLIA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEURAL STEM CELLS; NEUROGLIA;

EID: 84901505595     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800249-0.00001-9     Document Type: Chapter

References (333)

1. Abel T.W., Clark C., Bierie B., Chytil A., Aakre M., Gorska A., et al. GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Molecular Cancer Research 2009, 7:645-653. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19435821.
2. Ables J., Breunig J., Eisch A., Rakic P. Not(ch) just development: Notch signalling in the adult brain. Nature Reviews. Neuroscience 2011, 12:269-283.
3. Abounader R., Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology 2005, 7(4):436-451. 10.1215/S1152851705000050.
4. Aguilar-Morante D., Cortes-Canteli M., Sanz-Sancristobal M., Santos A., Perez-Castillo A. Decreased CCAAT/enhancer binding protein β expression inhibits the growth of glioblastoma cells. Neuroscience 2011, 176:110-119.
5. Akhavan D., Cloughesy T.F., Mischel P.S. mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro-Oncology 2010, 12(8):882-889. 10.1093/neuonc/noq052.
6. Akhavan D., Pourzia A.L., Nourian A.A., Williams K.J., Nathanson D., Babic I., et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery 2013, 3(5):534-547. 10.1158/2159-8290.CD-12-0502.
7. Alcantara Llaguno S., Chen J., Kwon C.-H., Jackson E.L., Li Y., Burns D.K., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19111880.
8. Anido J., Sáez-Borderías A., Gonzàlez-Juncà A., Rodón L., Folch G., Carmona M.A., et al. TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010, 18(6):655-668. 10.1016/j.ccr.2010.10.023.
9. Atai N.A., Renkema-Mills N.A., Bosman J., Schmidt N., Rijkeboer D., Tigchelaar W., et al. Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 2011, 59:489-503. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3201175&tool=pmcentrez&rendertype=abstract.
10. Auvergne R.M., Sim F.J., Wang S., Chandler-Militello D., Burch J., Al Fanek Y., et al. Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Reports 2013, 3:1-15. 10.1016/j.celrep.2013.04.035.
11. Bachoo R.M., Maher E.A., Ligon K.L., Sharpless N.E., Chan S.S., You M.J., et al. Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002, 1:269-277. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12086863.
12. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica 2008, 116(6):597-602.
13. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R.E., et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Research 2008, 68:6043-6048. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2739001&tool=pmcentrez&rendertype=abstract.
14. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/17051156.
15. Barkovich K.J., Hariono S., Garske A.L., Zhang J., Blair J.A., Fan Q.-W., et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discovery 2012, 2(5):450-457. 10.1158/2159-8290.CD-11-0287.
16. Batchelor T.T., Duda D.G., Di Tomaso E., Ancukiewicz M., Plotkin S.R., Gerstner E., et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Journal of Clinical Oncology 2010, 28:2817-2823. 10.1200/JCO.2009.26.3988.
17. Baumann P., Mandl-Weber S., Oduncu F., Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Experimental Cell Research 2009, 315(3):485-497. 10.1016/j.yexcr.2008.11.007.
18. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics 2008, 40:499-507. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/18443585.
19. Bettegowda C., Agrawal N., Jiao Y., Sausen M., Wood L.D., Hruban R.H. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011, 333(6048):1453-1455.
20. Bhat K.P.L., Balasubramaniyan V., Vaillant B., Ezhilarasan R., Hummelink K., Hollingsworth F., et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24:331-346. 10.1016/j.ccr.2013.08.001.
21. Bhat K.P.L., Salazar K.L., Balasubramaniyan V., Wani K., Heathcock L., Hollingsworth F., et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes & Development 2011, 25:2594-2609. 10.1101/gad.176800.111.
22. Bielen A., Perryman L., Box G.M., Valenti M., de Haven Brandon A., Martins V., et al. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Molecular Cancer Therapeutics 2011, 10(8):1407-1418. 10.1158/1535-7163.MCT-11-0205.
23. Bjerke L., Mackay A., Nandhabalan M., Burford A., Jury A., Popov S., et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discovery 2013, 3:512-519.
24. Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., et al. IDH1mutations at residue p.R132 (IDH1 R132) occur frequently in high-grade gliomas but not in other solid tumors. Human Mutation 2009, 30(1):7-11.
25. Boult J.K.R., Terkelsen J., Walker-Samuel S., Bradley D.P., Robinson S.P. A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment. PLoS One 2013, 8(4):e63024. 10.1371/journal.pone.0063024.
26. Bouvier-Labit C., Liprandi A., Monti G., Pellissier J.F., Figarella-Branger D. CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans. Journal of Neuro-Oncology 2002, 60:127-134. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12635659.
27. Bralten L.B.C., Kloosterhof N.K., Balvers R., Sacchetti A., Lapre L., Lamfers M., et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Annals of Neurology 2011, 69(3):455-463.
28. Brennan C., Momota H., Hambardzumyan D., Ozawa T., Tandon A., Pedraza A., et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009, 4(11):e7752. C. Creighton, Ed. 10.1371/journal.pone.0007752.
29. Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushermehr H., Salama S.R. The somatic genomic landscape of glioblastoma. Cell 2013, 155(2):462-477.
30. Briceño E., Calderon A., Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surgical Neurology 2007, 67(4):388-391. 10.1016/j.surneu.2006.08.080.
31. Broniscer A., Baker S.D., Wetmore C., Pai Panandiker A.S., Huang J., Davidoff A.M., et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2013, 19(11):3050-3058. 10.1158/1078-0432.CCR-13-0306.
32. Cao P., Maira S.-M., García-Echeverría C., Hedley D.W. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. British Journal of Cancer 2009, 100(8):1267-1276. 10.1038/sj.bjc.6604995.
33. Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P., et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298:1039-1043. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12351676.
34. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. The Journal of Clinical Investigation 2008, 118(9):3065-3074. 10.1172/JCI34739.
35. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2009, 463(7279):318-325.
36. Chan K.-M., Fang D., Gan H., Hashizume R., Yu C., Schroeder M., et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes & Development 2013, 27(9):985-990.
37. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16(22):5424-5435. 10.1158/1078-0432.CCR-10-1102.
38. Chaturvedi A., Araujo Cruz M.M., Jyotsana N., Sharma A., Yun H., Görlich K., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013, 122:2877-2887. 10.1182/blood-2013-03-491571.
39. Chaumeil M.M., Larson P.E.Z., Yoshihara H.A.I., Danforth O.M., Vigneron D.B., Nelson S.J., et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nature Communications 2013, 4:2429.
40. Chen H.-L., Chew L.-J., Packer R.J., Gallo V. Modulation of the Wnt/beta-catenin pathway in human oligodendroglioma cells by Sox17 regulates proliferation and differentiation. Cancer Letters 2013, 335(2):361-371.
41. Chen J., Li Y., Yu T.-S., McKay R.M., Burns D.K., Kernie S.G., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488(7412):522-526.
42. Cheng C.K., Fan Q.-W., Weiss W.A. PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathology 2009, 19(1):112-120. 10.1111/j.1750-3639.2008.00233.x.
43. Chew L.-J., Shen W., Ming X., Senatorov V.V., Chen H.-L., Cheng Y., et al. SRY-box containing gene 17 regulates the Wnt/β-catenin signaling pathway in oligodendrocyte progenitor cells. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2011, 31(39):13921-13935.
44. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-Miswritten, misinterpreted and mis-erased in human cancers. Nature Reviews. Cancer 2010, 10(7):457-469.
45. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Research 2010, 70(20):8097-8107. 10.1158/0008-5472.CAN-10-1814.
46. Chow L.M.L., Endersby R., Zhu X., Rankin S., Qu C., Zhang J., et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011, 19:305-316. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3060664&tool=pmcentrez&rendertype=abstract.
47. Clement V., Sanchez P., De Tribolet N., Radovanovic I., Ruiz I., Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Current Biology 2007, 17:165-172. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/17196391.
48. Combs S.E., Heeger S., Haselmann R., Edler L., Debus J., Schulz-Ertner D. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-Phase I/II trial: Study protocol. BMC Cancer 2006, 6:133. 10.1186/1471-2407-6-133.
49. Conway G.D., O'Bara M.A., Vedia B.H., Pol S.U., Sim F.J. Histone deacetylase activity is required for human oligodendrocyte progenitor differentiation. Glia 2012, 60:1944-1953. 10.1002/glia.22410.
50. Cooper L.A.D., Gutman D.A., Chisolm C., Appin C., Kong J., Rong Y., et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. American Journal of Pathology 2012, 180(5):2108-2119.
51. Cooper L.A.D., Gutman D.A., Long Q., Johnson B.A., Cholleti S.R., Kurc T., et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PloS One 2010, 5(9):e12548. 10.1371/journal.pone.0012548.
52. Craene B.De, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer 2013, 13(2):97-110.
53. Creyghton M.P., Cheng A.W., Welstead G.G., Kooistra T., Carey B.W., Steine E.J., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(50):21931-21936.
54. Dahmane N., Sánchez P., Gitton Y., Palma V., Sun T., Beyna M., et al. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development (Cambridge, England) 2001, 128:5201-5212. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11748155.
55. Dai C., Celestino J.C., Okada Y., Louis D.N., Fuller G.N., Holland E.C. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes & Development 2001, 15:1913-1925. 10.1101/gad.903001.
56. Dai C., Lyustikman Y., Shih A., Hu X., Fuller G.N., Rosenblum M., et al. The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 2005, 7:397-406. 10.1593/neo.04691.
57. Dawson M.R.L., Polito A., Levine J.M., Reynolds R. NG2-expressing glial progenitor cells: An abundant and widespread population of cycling cells in the adult rat CNS. Molecular and Cellular Neurosciences 2003, 24:476-488. Retrieved from. http://linkinghub.elsevier.com/retrieve/pii/S1044743103002100.
58. De Bacco F., Casanova E., Medico E., Pellegatta S., Orzan F., Albano R., et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Research 2012, 72(17):4537-4550.
59. De Groot J.F., Prados M., Urquhart T., Robertson S., Yaron Y., Sorensen A.G., et al. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. Journal of Clinical Oncology 2009, 27(15s):2047. Retrieved from, ASCO Meeting Abstracts. http://meeting.ascopubs.org/cgi/content/abstract/27/15S/204.
60. Deleyrolle L.P., Harding A., Cato K., Siebzehnrubl F.A., Rahman M., Azari H., et al. Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain: A journal of neurology 2011, 134:1331-1343. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3097894&tool=pmcentrez&rendertype=abstract.
61. De Witt Hamer P. Small molecule kinase inhibitors in glioblastoma: A systematic review of clinical studies. Neuro-Oncology 2010, 12(3):304-316.
62. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19064739.
63. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458(7239):780-783.
64. Ding H., Shannon P., Lau N., Wu X., Roncari L., Baldwin R.L., et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Research 2003, 55:1106-1113. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12615729.
65. Doetsch F. The glial identity of neural stem cells. Nature Neuroscience 2003, 6:1127-1134. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/14583753.
66. Doherty L., Gigas D.C., Kesari S., Drappatz J., Kim R., Zimmerman J., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006, 67(1):156-158. 10.1212/01.wnl.0000223844.77636.29.
67. Dong Y., Jia L., Wang X., Tan X., Xu J., Deng Z., et al. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. International Journal of Oncology 2011, 38(2):555-569. 10.3892/ijo.2010.861.
68. Drappatz J., Norden A.D., Wong E.T., Doherty L.M., LaFrankie D.C., Ciampa A., et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics 2010, 78(1):85-90. Retrieved from. http://www.sciencedirect.com/science/article/pii/S0360301609029319.
69. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine 2001, 344(14):1031-1037.
70. Dunn G.P., Rinne M.L., Wykosky J., Genovese G., Quayle S.N., Dunn I.F., et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development 2012, 26(8):756-784. 10.1101/gad.187922.112.
71. Easwaran H., Johnstone S., Vanneste L., Ohm J., Mosbruger T., Wang Q., et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Research 2012, 22:837-849. 10.1101/gr.131169.111.
72. Eller J.L., Longo S.L., Kyle M.M., Bassano D. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005, 56(1):155-162. 10.1227/01.NEU.0000145865.25689.55.
73. Elson A., Deng C., Campos-Torres J., Donehower L.A., Leder P. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 1995, 11(1):181-190.
74. Engler J.R., Robinson A.E., Smirnov I., Hodgson J.G., Berger M.S., Gupta N., et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PloS One 2012, 7(8):e43339. 10.1371/journal.pone.0043339.
75. Eriksson P.S., Perfilieva E., Bjork-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., et al. Neurogenesis in the adult human hippocampus. Nature Medicine 1998, 4:1313-1317. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9809557.
76. Fan Q.-W., Cheng C.K., Nicolaides T.P., Hackett C.S., Knight Z.A., Shokat K.M., et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Research 2007, 67(17):7960-7965. 10.1158/0008-5472.CAN-07-2154.
77. Fan Q.-W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer cell 2006, 9(5):341-349. 10.1016/j.ccr.2006.03.029.
78. Fan Q.-W., Weiss W.A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: Overcoming resistance. Current Topics in Microbiology and Immunology 2010, 347:279-296. 10.1007/82_2010_67.
79. Fancy S.P.J., Harrington E.P., Yuen T.J., Silbereis J.C., Zhao C., Baranzini S.E., et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nature Neuroscience 2011, 14:1009-1016. 10.1038/nn.2855.
80. Fathi A.T., Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Advances in Hematology 2012, 2012(12):1-12.
81. Ferent J., Zimmer C., Durbec P., Ruat M., Traiffort E. Sonic Hedgehog signaling is a positive oligodendrocyte regulator during demyelination. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2013, 33:1759-1772. 10.1523/JNEUROSCI.3334-12.2013.
82. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18(6):553-567. 10.1016/j.ccr.2010.11.015.
83. Finger E.C., Giaccia A.J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer and Metastasis Reviews 2010, 29(2):285-293.
84. Flavahan W.A., Wu Q., Hitomi M., Rahim N., Kim Y., Sloan A.E., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature Neuroscience 2013, 16:1373-1382.
85. Flores A.I., Mallon B.S., Matsui T., Ogawa W., Rosenzweig A., Okamoto T., et al. Akt-mediated survival of oligodendrocytes induced by neuregulins. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2000, 20(20):7622-7630. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11027222.
86. Forsberg-Nilsson K., Behar T.N., Afrakhte M., Barker J.L., McKay R.D. Platelet-derived growth factor induces chemotaxis of neuroepithelial stem cells. Journal of Neuroscience Research 1998, 53:521-530. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/9726423.
87. Friedmann-Morvinski D., Bushong E.A., Ke E., Soda Y., Marumoto T., Singer O., et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012, 338:1080-1084. 10.1126/science.1226929.
88. Gajadhar A.S., Bogdanovic E., Muñoz D.M., Guha A. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Molecular Cancer Research: MCR 2012, 10(3):428-440. 10.1158/1541-7786.MCR-11-0531.
89. Gan H.K., Kaye A.H., Luwor R.B. The EGFRvIII variant in glioblastoma multiforme. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 2009, 16(6):748-754. 10.1016/j.jocn.2008.12.005.
90. Garner J.M., Fan M., Yang C.H., Du Z., Sims M., Davidoff A.M., et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor B signaling in glioblastoma cancer stem cells regulates the notch pathway. Journal of Biological Chemistry 2013, 288(36):26167-26176.
91. Gavalas A., Trainor P., Ariza-McNaughton L., Krumlauf R. Synergy between Hoxa1 and Hoxb1: The relationship between arch patterning and the generation of cranial neural crest. Development (Cambridge, England) 2001, 128(15):3017-3027. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11532923.
92. Gerstner E.R., Chen P.-J., Wen P.Y., Jain R.K., Batchelor T.T., Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-Oncology 2010, 12(5):466-472. 10.1093/neuonc/nop051.
93. Gerstner E.R., Eichler A.F., Plotkin S.R., Drappatz J., Doyle C.L., Xu L., et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. Journal of Neuro-Oncology 2011, 103(2):325-332. 10.1007/s11060-010-0390-7.
94. Ghildiyal R., Dixit D., Sen E. EGFR inhibitor BIBU induces apoptosis and defective autophagy in glioma cells. Molecular Carcinogenesis 2013, 52:970-982. 10.1002/mc.21938.
95. Godard S., Getz G., Delorenzi M., Farmer P., Kobayashi H., Desbaillets I., et al. Classification of human astrocytic gliomas on the basis of gene expression: A correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Research 2003, 63(20):6613-6625.
96. Gravendeel L.A.M., Kloosterhof N.K., Bralten L.B.C., van Marion R., Dubbink H.J., Dinjens W., et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Human Mutation 2010, 31(3):E1186-E1199.
97. Gu F., Hata R., Ma Y.-J., Tanaka J., Mitsuda N., Kumon Y., et al. Suppression of Stat3 promotes neurogenesis in cultured neural stem cells. Journal of Neuroscience Research 2005, 81(2):163-171.
98. Gutman D.A., Cooper L.A.D., Hwang S.N., Holder C.A., Gao J., Aurora T.D., et al. MR imaging predictors of molecular profile and survival: Multi-institutional study of the TCGA glioblastoma data set. Radiology 2013, 267(2):560-569.
99. Haas-Kogan D.A., Prados M.D., Tihan T., Eberhard D.A., Jelluma N., Arvold N.D., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. Journal of the National Cancer Institute 2005, 97(12):880-887. 10.1093/jnci/dji161.
100. Hall A., Giese N.A., Richardson W.D. Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development (Cambridge, England) 1996, 122:4085-4094. Retrieved from. http://discovery.ucl.ac.uk/109515/.
101. Han Y., Caday C.G., Umezawa K., Nanda A. Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate. Oncology Research 1997, 9:581-587.
102. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathologica 2009, 118(4):469-474.
103. He J., Liu Y., Zhu T., Zhu J., Dimeco F., Vescovi A.L., et al. CD90 is identified as a marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Molecular Cellular Proteomics: MCP 2011, 11:1-24. 10.1074/mcp.M111.010744.
104. Hébert J.M., Fishell G. The genetics of early telencephalon patterning: Some assembly required. Nature Reviews Neuroscience 2008, 9:678-685. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2669317&tool=pmcentrez&rendertype=abstract.
105. Hede S.-M., Hansson I., Afink G.B., Eriksson A., Nazarenko I., Andrae J., et al. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background. Glia 2009, 57:1143-1153. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19115382.
106. Hill R.A., Patel K.D., Medved J., Reiss A.M., Nishiyama A. NG2 cells in white matter but not gray matter proliferate in response to PDGF. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2013, 33(36):14558-14566. 10.1523/JNEUROSCI.2001-12.2013.
107. Hochstim C., Deneen B., Lukaszewicz A., Zhou Q., Anderson D.J. Identification of positionally distinct astrocyte subtypes whose identities are specified by a homeodomain code. Cell 2008, 133:510-522. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/18455991.
108. Hodgson J.G., Yeh R.-F., Ray A., Wang N.J., Smirnov I., Yu M., et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro-Oncology 2009, 11(5):477-487.
109. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature Genetics 2000, 25:55-57. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/10802656.
110. Holland Eric C., Hively W.P., DePinho R.A., Varmus H.E. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes & Development 1998, 12:3675-3685. Retrieved from. http://www.genesdev.org/cgi/doi/10.1101/gad.12.23.3675.
111. Homma J., Yamanaka R., Yajima N., Tsuchiya N., Genkai N., Sano M., et al. Increased expression of CCAAT/enhancer binding protein β correlates with prognosis in glioma patients. Oncology Reports 2006, 15(3):595-601.
112. Hong J.-H., Yaffe M.B. TAZ: A beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 2006, 5(2):176-179.
113. Houillier C., Wang X., Kaloshi G., Mokhtari K., Guillevin R., Laffaire J., et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010, 75(17):1560-1566.
114. Hu X., Pandolfi P.P., Li Y., Koutcher J.A., Rosenblum M., Holland E.C. mTOR promotes survival and astrocytic characteristics induced by Pten/Akt signaling in glioblastoma1. Neoplasia 2005, 7:356-368. Retrieved from. http://www.ingentaselect.com/rpsv/cgi-bin/cgi?ini=xref&body=linker&reqdoi=10.1593/neo.04595.
115. Hu X.-L., Wang Y., Shen Q. Epigenetic control on cell fate choice in neural stem cells. Protein & Cell 2012, 3(4):278-290.
116. Hughes E.G., Kang S.H., Fukaya M., Bergles D.E. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nature Neuroscience 2013, 16:668-676. Retrieved from. http://www.nature.com/doifinder/10.1038/nn.3390.
117. Huse J.T., Holland E.C. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Reviews Cancer 2010, 10:319-331. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/20414201.
118. Ichimura K., Pearson D.M., Kocialkowski S., Bäcklund L.M., Chan R., Jones D.T.W., et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology 2009, 11(4):341-347.
119. Ishii A., Furusho M., Bansal R. Sustained activation of ERK1/2 MAPK in oligodendrocytes and schwann cells enhances myelin growth and stimulates oligodendrocyte progenitor expansion. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2013, 33(1):175-186. 10.1523/JNEUROSCI.4403-12.2013.
120. Ivkovic S., Canoll P., Goldman J.E. Constitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matter. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2008, 28(4):914-922. 10.1523/JNEUROSCI.4327-07.2008.
121. Iwamoto F.M. trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06). Neuro-Oncology 2010, 12(8):855-861. Retrieved from. http://neuro-oncology.oxfordjournals.org/content/12/8/855.short.
122. Jacques T.S., Swales A., Brzozowski M.J., Henriquez N.V., Linehan J.M., Mirzadeh Z., et al. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. The European Molecular Biology Organization Journal 2010, 29:222-235. 10.1038/emboj.2009.327.
123. Jensen N.A., Pedersen K.M., Lihme F., Rask L., Nielsen J.V., Rasmussen T.E., et al. Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas. The Journal of Biological Chemistry 2003, 278:8300-8308. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12501251.
124. Jin G., Pirozzi C.J., Chen L.H., Lopez G.Y., Duncan C.G., Feng J., et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 2012, 3(8):774-782.
125. Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. The Journal of Biological Chemistry 2000, 275(12):8806-8811.
126. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692. 10.1016/j.cell.2007.01.029.
127. Joo K.M., Jin J., Kim E., Ho Kim K., Kim Y., Gu Kang B., et al. MET signaling regulates glioblastoma stem cells. Cancer Research 2012, 72:3828-3838. 10.1158/0008-5472.CAN-11-3760.
128. Joshi A.D., Loilome W., Siu I.-M., Tyler B., Gallia G.L., Riggins G.J. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PloS One 2012, 7(10):e44372. 10.1371/journal.pone.0044372.
129. Kalani M.Y.S., Cheshier S.H., Cord B.J., Bababeygy S.R., Vogel H., Weissman I.L., et al. Wnt-mediated self-renewal of neural stem/progenitor cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16970-16975. 10.1073/pnas.0808616105.
130. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. The Journal of Clinical Investigation 2009, 119(6):1420-1428.
131. Kang M.R., Kim M.S., Oh J.E., Kim Y.R., Song S.Y., Seo S.I., et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. International Journal of Cancer 2009, 125(2):353-355.
132. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death and Differentiation 2004, 11(4):448-457. 10.1038/sj.cdd.4401359.
133. Katz A.M., Amankulor N.M., Pitter K., Helmy K., Squatrito M., Holland E.C. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PloS One 2012, 7(2):e32453. 10.1371/journal.pone.0032453.
134. Kawauchi D., Robinson G., Uziel T., Gibson P., Rehg J., Gao C., et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer cell 2012, 21(2):168-180.
135. Kessaris N., Fogarty M., Iannarelli P., Grist M., Wegner M., Richardson W.D. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nature Neuroscience 2006, 9:173-179. 10.1038/nn1620.
136. Keunen O., Johansson M., Oudin A., Sanzey M., Rahim S.A.A., Fack F., et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:3749-3754. 10.1073/pnas.1014480108.
137. Khuong-Quang D.-A., Buczkowicz P., Rakopoulos P., Liu X.-Y., Fontebasso A.M., Bouffet E., et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica 2012, 124(3):439-447.
138. Kilpatrick T.J., Bartlett P.F. Cloned multipotential precursors from the mouse cerebrum require FGF-2, whereas glial restricted precursors are stimulated with either FGF-2 or EGF. Journal of Neuroscience 1995, 15:3653-3661. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/7751935.
139. Kim Y., Kim E., Wu Q., Guryanova O., Hitomi M., Lathia J.D., et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes & Development 2012, 26:1247-1262. 10.1101/gad.193565.112.
140. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. The Journal of Clinical Investigation 2010, 120(3):694-705.
141. Koirala S., Corfas G. Identification of novel glial genes by single-cell transcriptional profiling of bergmann glial cells from mouse cerebellum. PLoS ONE 2010, 5:15. 10.1371/journal.pone.0009198.
142. Koochekpour S., Jeffers M., Rulong S., Taylor G., Klineberg E., Hudson E.A., et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Research 1997, 57(23):5391-5398.
143. Kraus A.C., Ferber I., Bachmann S.-O., Specht H., Wimmel A., Gross M.W., et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002, 21(57):8683-8695.
144. Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27(5):740-745. 10.1200/JCO.2008.16.3055.
145. Kreisl T.N., Lassman A.B., Mischel P.S., Rosen N., Scher H.I., Teruya-Feldstein J., et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). Journal of Neuro-Oncology 2009, 92(1):99-105. 10.1007/s11060-008-9741-z.
146. Kwon C.-H., Zhao D., Chen J., Alcantara S., Li Y., Burns D.K., et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Research 2008, 68:3286-3294. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2760841&tool=pmcentrez&rendertype=abstract.
147. Labussière M., Idbaih A., Wang X.-W., Marie Y., Boisselier B., Falet C., et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010, 74(23):1886-1890.
148. Lai A., Kharbanda S., Pope W.B., Tran A., Solis O.E., Peale F., et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(34):4482-4490. 10.1200/JCO.2010.33.8715.
149. Langseth A.J., Munji R.N., Choe Y., Huynh T., Pozniak C.D., Pleasure S.J. Wnts influence the timing and efficiency of oligodendrocyte precursor cell generation in the telencephalon. Journal of Neuroscience 2010, 30:13367-13372. Retrieved from. http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1934-10.2010.
150. Lasiene J., Matsui A., Sawa Y., Wong F., Horner P.J. Age-related myelin dynamics revealed by increased oligodendrogenesis and short internodes. Aging Cell 2009, 8:201-213. Retrieved from. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703583/?tool=pubmed.
151. Lathia Justin D., Gallagher J., Heddleston J.M., Wang J., Eyler C.E., Macswords J., et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2884275&tool=pmcentrez&rendertype=abstract.
152. Lathia J.D., Hitomi M., Gallagher J., Gadani S.P., Adkins J., Vasanji A., et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Disease 2011, 2:e200. 10.1038/cddis.2011.80.
153. Lee T.I., Jenner R.G., Boyer L.A., Guenther M.G., Levine S.S., Kumar R.M., et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006, 125:301-313. Retrieved from. http://discovery.ucl.ac.uk/7048/.
154. Lee E.Q., Kuhn J., Lamborn K.R., Abrey L., DeAngelis L.M., Lieberman F., et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology 2012, 14(12):1511-1518. 10.1093/neuonc/nos264.
155. Lee J.C., Vivanco I., Beroukhim R., Huang J.H.Y., Feng W.L., DeBiasi R.M., et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Medicine 2006, 3(12):e485. A. Lassman, Ed.
156. Lei L., Sonabend A.M., Guarnieri P., Soderquist C., Ludwig T., Rosenfeld S., et al. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS ONE 2011, 6:e20041. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3100315&tool=pmcentrez&rendertype=abstract.
157. Lei Q.-Y., Zhang H., Zhao B., Zha Z.-Y., Bai F., Pei X.-H., et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and Cellular Biology 2008, 28(7):2426-2436.
158. Lelievre V., Ghiani C.A., Seksenyan A., Gressens P., De Vellis J., Waschek J.A. Growth factor-dependent actions of PACAP on oligodendrocyte progenitor proliferation. Regulatory Peptides 2006, 137:58-66. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16989910.
159. Lewis P.W., Müller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340(6134):857-861.
160. Li X., Huang Y., Jiang J., Frank S.J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cellular Signalling 2008, 20:2145-2155. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2613789&tool=pmcentrez&rendertype=abstract.
161. Li Y., Li A., Glas M., Lal B., Ying M., Sang Y., et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:9951-9956. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3116406&tool=pmcentrez&rendertype=abstract.
162. Ligon K.L., Kesari S., Kitada M., Sun T., Arnett H.A., Alberta J.A., et al. Development of NG2 neural progenitor cells requires Olig gene function. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7853-7858. 10.1073/pnas.0511001103.
163. Lin C.-J., Lee C.-C., Shih Y.-L., Lin C.-H., Wang S.-H., Chen T.-H., et al. Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PloS One 2012, 7(6):e38706. 10.1371/journal.pone.0038706.
164. Lindberg N., Kastemar M., Olofsson T., Smits A., Uhrbom L. Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma. Oncogene 2009, 28:2266-2275. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19421151.
165. Liu W., Fu Y., Xu S., Ding F., Zhao G., Zhang K., et al. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia 2011, 18(1):119-121. 10.1016/j.jocn.2010.05.010.
166. Liu F.-J., Gui S.-B., Li C.-Z., Sun Z.-L., Zhang Y.-Z., Academy C. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44. Chinese Medical Journal 2008, 121(17):1702-1706.
167. Liu T.-J., Koul D., LaFortune T., Tiao N., Shen R.J., Maira S.-M., et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Molecular Cancer Therapeutics 2009, 8(8):2204-2210. 10.1158/1535-7163.MCT-09-0160.
168. Liu C., Sage J.C., Miller M.R., Verhaak R.G.W., Hippenmeyer S., Vogel H., et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011, 146(2):209-221. 10.1016/j.cell.2011.06.014.
169. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 2006, 5:67. 10.1186/1476-4598-5-67.
170. Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.-J., Anders R.A., et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes & Development 2012, 26(12):1300-1305.
171. Lo H.-W. EGFR-targeted therapy in malignant glioma: Novel aspects and mechanisms of drug resistance. Current Molecular Pharmacology 2010, 3(1):37-52.
172. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007, 114(2):97-109. 10.1007/s00401-007-0243-4.
173. Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22(1):21-35. 10.1016/j.ccr.2012.05.037.
174. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2013, 483(7390):474-478.
175. Luchman H.A., Stechishin O.D., Dang N.H., Blough M.D., Chesnelong C., Kelly J.J., et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology 2012, 14(2):184-191.
176. Lu-Emerson C., Norden A.D., Drappatz J., Quant E.C., Beroukhim R., Ciampa A.S., et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. Journal of Neuro-Oncology 2011, 104(1):287-291. 10.1007/s11060-010-0489-x.
177. Lumsden A., Krumlauf R. Patterning the vertebrate neuraxis. Science 1996, 274(5290):1109-1115. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/8895453.
178. Machold R., Hayashi S., Rutlin M., Muzumdar M.D., Nery S., Corbin J.G., et al. Sonic hedgehog is required for progenitor cell telencephalic stem cell niches. Neuron 2003, 39:937-950.
179. Maira S.-M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics 2008, 7(7):1851-1863. 10.1158/1535-7163.MCT-08-0017.
180. Mallini P., Lennard T., Kirby J., Meeson A. Epithelial-to-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistance. Cancer Treatment Reviews 2014, 40:341-348.
181. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4):704-715.
182. Mao P., Joshi K., Li J., Kim S.-H., Li P., Santana-Santos L., et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(21):8644-8649. 10.1073/pnas.1221478110.
183. Marumoto T., Tashiro A., Friedmann-Morvinski D., Scadeng M., Soda Y., Gage F.H., et al. Development of a novel mouse glioma model using lentiviral vectors. Nature Medicine 2009, 15:110-116. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19122659.
184. Mazzoleni S., Politi L.S., Pala M., Cominelli M., Franzin A., Sergi Sergi L., et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Research 2010, 70(19):7500-7513. 10.1158/0008-5472.CAN-10-2353.
185. Mehta S., Huillard E., Kesari S., Maire C.L., Golebiowski D., Harrington E.P., et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011, 19(3):359-371.
186. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine 2005, 353(19):2012-2024. 10.1056/NEJMoa051918.
187. Ménard C., Hein P., Paquin A., Savelson A., Yang X.M., Lederfein D., et al. An essential role for a MEK-C/EBP pathway during growth factor-regulated cortical neurogenesis. Neuron 2002, 36(4):597-610.
188. Merkle F.T., Mirzadeh Z., Alvarez-Buylla A. Mosaic organization of neural stem cells in the adult brain. Science 2007, 317:381-384. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/17615304.
189. Mikheeva S.A., Mikheev A.M., Petit A., Beyer R., Oxford R.G., Khorasani L., et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Molecular Cancer 2010, 9:194.
190. Mineo J.-F., Bordron A., Baroncini M., Maurage C.-A., Ramirez C., Siminski R.-M., et al. Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. Journal of Neuro-Oncology 2007, 85(3):281-287. 10.1007/s11060-007-9424-1.
191. Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K., et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/12787504.
192. Monje M., Mitra S.S., Freret M.E., Raveh T.B., Kim J., Masek M., et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(11):4453-4458.
193. Moon J.-H., Kwon S., Jun E.K., Kim A., Whang K.Y., Kim H., et al. Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells. Biochemical and Biophysical Research Communications 2011, 412:175-181. 10.1016/j.bbrc.2011.07.070.
194. Moransard M., Sawitzky M., Fontana A., Suter T. Expression of the HGF receptor c-met by macrophages in experimental autoimmune encephalomyelitis. Glia 2010, 58:559-571. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19941340.
195. Morris P.G., Abrey L.E. Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas. Targeted Oncology 2010, 5(3):193-200. 10.1007/s11523-010-0160-7.
196. Muhic A., Poulsen H.S., Sorensen M., Grunnet K., Lassen U. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology 2013, 111(2):205-212. 10.1007/s11060-012-1009-y.
197. Nagane M., Narita Y., Mishima K., Levitzki A., Burgess A.W., Cavenee W.K., et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. Journal of Neurosurgery 2001, 95(3):472-479. 10.3171/jns.2001.95.3.0472.
198. Nakashima K. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999, 284(5413):479-482.
199. Navis A.C., Bourgonje A., Wesseling P., Wright A., Hendriks W., Verrijp K., et al. Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PloS One 2013, 8(3):e58262. 10.1371/journal.pone.0058262.
200. Nazarenko I., Hedrén A., Sjödin H., Orrego A., Andrae J., Afink G.B., et al. Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. PLoS ONE 2011, 6:14. 10.1371/journal.pone.0018303.
201. Neyns B., Sadones J., Chaskis C., Dujardin M., Everaert H., Lv S., et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 2011, 103(3):491-501. 10.1007/s11060-010-0402-7.
202. Nghiemphu P.L., Lai A., Green R.M., Reardon D.A., Cloughesy T. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. Journal of Neuro-Oncology 2012, 110(2):245-250. 10.1007/s11060-012-0960-y.
203. Niola F., Zhao X., Singh D., Sullivan R., Castano A., Verrico A., et al. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. The Journal of Clinical Investigation 2013, 123(1):405-417. 10.1172/JCI63811DS1.
204. Nishiyama A., Lin X.H., Giese N., Heldin C.H., Stallcup W.B. Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. Journal of Neuroscience Research 1996, 43:299-314. 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E.
205. Nobusawa S., Watanabe T., Kleihues P., Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15(19):6002-6007.
206. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17(5):510-522.
207. O'Reilly K.E., Rojo F., She Q.-B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 2006, 66(3):1500-1508. 10.1158/0008-5472.CAN-05-2925.
208. Ohya W., Funakoshi H., Kurosawa T., Nakamura T. Hepatocyte growth factor (HGF) promotes oligodendrocyte progenitor cell proliferation and inhibits its differentiation during postnatal development in the rat. Brain Research 2007, 1147:51-65. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/17382307.
209. Olar A., Aldape K.D. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current Treatment Options in Oncology 2012, 13:1-20. 10.1007/s11864-012-0210-8.
210. Pàez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Viñals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-231.
211. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Research 2001, 61(2):439-444.
212. Paquin A. CCAAT/enhancer-binding protein phosphorylation biases cortical precursors to generate neurons rather than astrocytes in vivo. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2005, 25(46):10747-10758.
213. Parsons D.W., Jones S., Zhang X., Lin J.C.-H., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/18772396.
214. Pei Y., Moore C.E., Wang J., Tewari A.K., Eroshkin A., Cho Y.-J., et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 2012, 21(2):155-167.
215. Persson A.I., Petritsch C., Swartling F.J., Itsara M., Sim F.J., Auvergne R., et al. Non-stem cell origin for oligodendroglioma. Cancer Cell 2010, 18:669-682. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3031116&tool=pmcentrez&rendertype=abstract.
216. Petryniak M.A., Potter G.B., Rowitch D.H., Rubenstein J.L.R. Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. Neuron 2007, 55:417-433. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2039927&tool=pmcentrez&rendertype=abstract.
217. Phillips J.J., Aranda D., Ellison D.W., Judkins A.R., Croul S.E., Brat D.J., et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathology 2013, 23(5):565-573.
218. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9(3):157-173. 10.1016/j.ccr.2006.02.019.
219. Piao Y., Liang J., Holmes L., Henry V., Sulman E., de Groot J.F. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2013, 19(16):4392-4403. 10.1158/1078-0432.CCR-12-1557.
220. Piao Y., Liang J., Holmes L., Zurita A.J., Henry V., Heymach J.V., et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology 2012, 14(11):1379-1392.
221. Piaskowski S., Bienkowski M., Stoczynska-Fidelus E., Stawski R., Sieruta M., Szybka M., et al. Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. British Journal of Cancer 2011, 104(6):968-970.
222. Piccolo S., Cordenonsi M., Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2013, 19(18):4925-4930.
223. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature Reviews. Cancer 2009, 9(4):265-273.
224. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483(7387):100-103. 10.1038/nature10868.
225. Priester M., Copanaki E., Vafaizadeh V., Hensel S., Bernreuther C., Glatzel M., et al. STAT3 silencing inhibits glioma single cell infiltration and tumor growth. Neuro-Oncology 2013, 15(7):840-852.
226. Purow B.W., Haque R.M., Noel M.W., Su Q., Burdick M.J., Lee J., et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Research 2005, 65:2353-2363. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/15781650.
227. Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine 2013, 19:1-12. 10.1038/nm.3337.
228. Raff M.C., Miller R.H., Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 1983, 303:390-396. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/6304520.
229. Raizer J.J., Abrey L.E. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology 2010, 12(1):95-103. Retrieved from. http://neuro-oncology.oxfordjournals.org/content/12/1/95.short.
230. Rakic P. Principles of neural cell migration. Experientia 1990, 46(9):882-891.
231. Rao R.D., Mladek A.C., Lamont J.D., Goble J.M., Erlichman C., James C.D., et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005, 7(10):921-929. 10.1593/neo.05361.
232. Rasper M., Schäfer A., Piontek G., Teufel J., Brockhoff G., Ringel F., et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncology 2010, 12:1024-1033. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3018920&tool=pmcentrez&rendertype=abstract.
233. Rath P., Lal B., Ajala O., Li Y., Xia S., Kim J., et al. In vivo c-Met pathway inhibition depletes human glioma xenografts of tumor-propagating stem-like cells. Translational Oncology 2013, 6(2):104-111.
234. Razis E., Selviaridis P., Labropoulos S., Norris J.L., Zhu M.-J., Song D.D., et al. Phase II study of neoadjuvant imatinib in glioblastoma: Evaluation of clinical and molecular effects of the treatment. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15(19):6258-6266. 10.1158/1078-0432.CCR-08-1867.
235. Reardon David A., Conrad C.A., Cloughesy T., Prados M.D., Friedman H.S., Aldape K.D., et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology 2012, 69(6):1507-1518. 10.1007/s00280-012-1854-6.
236. Reardon David A., Desjardins A., Vredenburgh J.J., Gururangan S., Friedman A.H., Herndon J.E., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology 2010, 96(2):219-230. 10.1007/s11060-009-9950-0.
237. Reardon D.A., Dresemann G., Taillibert S., Campone M., van den Bent M., Clement P., et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British Journal of Cancer 2009, 101(12):1995-2004. 10.1038/sj.bjc.6605411.
238. Reardon David A., Quinn J.A., Vredenburgh J.J., Gururangan S., Friedman A.H., Desjardins A., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12(3 Pt 1):860-868. 10.1158/1078-0432.CCR-05-2215.
239. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11689955.
240. Reznik T.E., Sang Y., Ma Y., Abounader R., Rosen E.M., Xia S., et al. Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Molecular Cancer Research: MCR 2008, 6(1):139-150. 10.1158/1541-7786.MCR-07-0236.
241. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/21102434.
242. Rickman D.S., Bobek M.P., Misek D.E., Kuick R., Blaivas M., Kurnit D.M., et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Research 2001, 61(18):6885-6891.
243. Roberts W.G., Whalen P.M., Soderstrom E., Moraski G., Lyssikatos J.P., Wang H.-F., et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Research 2005, 65(3):957-966. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/15705896.
244. Robinson J.P., Vanbrocklin M.W., Lastwika K.J., McKinney A.J., Brandner S., Holmen S.L. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene 2011, 30:1341-1350. Retrieved from. http://discovery.ucl.ac.uk/441249/.
245. Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340(6132):626-630.
246. Ronellenfitsch M.W., Steinbach J.P., Wick W. Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: Current clinical status and perspectives. Targeted Oncology 2010, 5(3):183-191. 10.1007/s11523-010-0154-5.
247. Saito N., Fu J., Zheng S., Yao J., Wang S., Liu D.D., et al. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor initiating cells. Stem Cells 2014, 32:301-312.
248. Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28(31):4722-4729. 10.1200/JCO.2010.28.6963.
249. Sanai N., Nguyen T., Ihrie R.A., Mirzadeh Z., Tsai H.-H., Wong M., et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature 2011, 478:1-6. 10.1038/nature10487.
250. Sandberg C.J., Altschuler G., Jeong J., Strømme K.K., Stangeland B., Murrell W., et al. Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. Experimental Cell Research 2013, 319:1-14. 10.1016/j.yexcr.2013.06.004.
251. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2009, 27(25):4150-4154.
252. Santiskulvong C., Konecny G.E., Fekete M., Chen K.-Y.M., Karam A., Mulholland D., et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17(8):2373-2384. 10.1158/1078-0432.CCR-10-2289.
253. Santoni M., Burattini L., Nabissi M., Beatrice Morelli M., Berardi R., Santoni G., et al. Essential role of gli proteins in glioblastoma multiforme. Current Protein and Peptide Science 2013, 14:8. Retrieved from. http://www.ingentaconnect.com.sci-hub.org/content/ben/cpps/2013/00000014/00000002/art00005.
254. Sasaki M., Knobbe C.B., Itsumi M., Elia A.J., Harris I.S., Chio I.I.C., et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes & Development 2012, 26(18):2038-2049.
255. Sasaki M., Knobbe C.B., Munger J.C., Lind E.F., Brenner D., Brüstle A., et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2013, 488(7413):656-659.
256. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1(3):289-298.
257. Schwartzentruber J., Korshunov A., Liu X.-Y., Jones D.T.W., Pfaff E., Jacob K., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482(7384):226-231.
258. Shannon P., Sabha N., Lau N., Kamnasaran D., Gutmann D.H., Guha A. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. The American Journal of Pathology 2005, 167:859-867. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1698742&tool=pmcentrez&rendertype=abstract.
259. Shawver L.K., Schwartz D.P., Mann E., Chen H., Tsai J., Chu L., et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1997, 3(7):1167-1177. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/9815796.
260. Shen J., Zheng H., Ruan J., Fang W., Li A., Tian G., et al. Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. British Journal of Cancer 2013, 109(1):164-171. 10.1038/bjc.2013.306.
261. Sher F., Boddeke E., Copray S. Ezh2 expression in astrocytes induces their dedifferentiation toward neural stem cells. Cellular Reprogramming 2011, 13:1-6. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/20979531.
262. Sher F., Boddeke E., Olah M., Copray S. Dynamic changes in Ezh2 gene occupancy underlie its involvement in neural stem cell self-renewal and differentiation towards oligodendrocytes. PLoS ONE 2012, 7:e40399.
263. Sher F., Rössler R., Brouwer N., Balasubramaniyan V., Boddeke E., Copray S. Differentiation of neural stem cells into oligodendrocytes: Involvement of the polycomb group protein Ezh2. Stem Cells 2008, 26:2875-2883. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/18687996.
264. Sherry M.M., Reeves A., Wu J.K., Cochran B.H. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009, 27(10):2383-2392.
265. Shih A.H., Dai C., Hu X., Shih A.H., Dai C., Hu X., et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Research 2004, 64:4783-4789.
266. Shimizu T., Kagawa T., Wada T., Muroyama Y., Takada S., Ikenaka K. Wnt signaling controls the timing of oligodendrocyte development in the spinal cord. Developmental Biology 2005, 282:397-410. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/15950605.
267. Shingu T., Fujiwara K., Bögler O., Akiyama Y., Moritake K., Shinojima N., et al. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. International Journal of Cancer 2009, 124(5):1060-1071. 10.1002/ijc.24030.
268. Siebzehnrubl F.A., Silver D.J., Tugertimur B., Deleyrolle L.P., Siebzehnrubl D., Sarkisian M.R., et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Molecular Medicine 2013, 5(8):1196-1212.
269. Sim F.J., McClain C.R., Schanz S.J., Protack T.L., Windrem M.S., Goldman S.A. CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells. Nature Biotechnology 2011, 29:934-941. 10.1038/nbt.1972.
270. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: Knowns and unknowns. Nature Reviews Molecular Cell Biology 2009, 10:697-708. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19738629.
271. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Research 2003, 63:5821-5828.
272. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401.
273. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010, 29(34):4741-4751.
274. Snuderl M., Fazlollahi L., Le L.P., Nitta M., Zhelyazkova B.H., Davidson C.J., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011, 20(6):810-817.
275. Son M.J., Woolard K., Nam D.-H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19427293.
276. Sotelo J., Briceño E., López-González M.A. Adding chloroquine to conventional treatment for glioblastoma multiforme: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2006, 144(5):337-343.
277. Sottile V., Li M., Scotting P.J. Stem cell marker expression in the Bergmann glia population of the adult mouse brain. Brain Research 2006, 1099(1):8-17.
278. Sottoriva A., Spiteri I., Piccirillo S.G.M., Touloumis A., Collins V.P., Marioni J.C., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proceedings of the National Academy of Sciences of the United States of America 2013, 110(10):4009-4014. 10.1073/pnas.1219747110.
279. Steiner L.A., Schulz V.P., Maksimova Y., Wong C., Gallagher P.G. Patterns of histone H3 lysine 27 monomethylation and erythroid cell type-specific gene expression. The Journal of Biological Chemistry 2011, 286(45):39457-39465.
280. Stolt C.C., Lommes P., Sock E., Chaboissier M.-C., Schedl A., Wegner M. The Sox9 transcription factor determines glial fate choice in the developing spinal cord. Genes & Development 2003, 17:1677-1689. 10.1101/gad.259003.
281. Stolt C., Schlierf A., Lommes P., Hillgartner S., Werner T., Kosian T., et al. SoxD proteins influence multiple stages of oligodendrocyte development and modulate SoxE protein function. Developmental Cell 2006, 11:697-709. Retrieved from. http://discovery.ucl.ac.uk/143376/.
282. Stommel J., Kimmelman A., Ying H. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 287(2007). 10.1126/science.1142946.
283. Sturm D., Witt H., Hovestadt V., Khuong-Quang D.-A., Jones D.T.W., Konermann C., et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22(4):425-437.
284. Sugiarto S., Persson A.I., Munoz E.G., Waldhuber M., Lamagna C., Andor N., et al. Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell 2011, 20:328-340. Retrieved from. http://linkinghub.elsevier.com/retrieve/pii/S1535610811003084.
285. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., et al. Activation of Akt and eIF4E survival pathways by rapamycin mediated mammalian target of rapamycin inhibition. Cancer Research 2005, 65:7052-7058.
286. Suvà M.-L., Riggi N., Janiszewska M., Radovanovic I., Provero P., Stehle J.-C., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Research 2009, 69:9211-9218. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19934320.
287. Szerlip N.J., Pedraza A., Chakravarty D., Azim M., McGuire J., Fang Y., et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(8):3041-3046. 10.1073/pnas.1114033109.
288. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676. 10.1016/j.cell.2006.07.024.
289. Tchoghandjian A., Baeza N., Colin C., Cayre M., Metellus P., Beclin C., et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathology 2010, 20(1):211-221.
290. Tekki-Kessaris N., Woodruff R., Hall A.C., Gaffield W., Kimura S., Stiles C.D., et al. Hedgehog-dependent oligodendrocyte lineage specification in the telencephalon. Development (Cambridge, England) 2001, 128:2545-2554. Retrieved from. http://discovery.ucl.ac.uk/10570/.
291. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068. 10.1038/nature07385.
292. Thiery J.P. Epithelial-Mesenchymal transitions in tumour progression. Nature Reviews Cancer 2002, 2(6):442-454.
293. Trainor P.A., Krumlauf R. Hox genes, neural crest cells and branchial arch patterning. Current Opinion in Cell Biology 2001, 13(6):698-705. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/11698185.
294. Tsai H.-H., Li H., Fuentealba L.C., Molofsky A.V., Taveira-Marques R., Zhuang H., et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science 2012, 358:1-15. 10.1126/science.1222381.
295. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2013, 483(7390):479-483.
296. Uhrbom L., Dai C., Celestino J.C., Rosenblum M.K., Fuller G.N., Holland E.C. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Research 2002, 62:5551-5558. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12359767.
297. Valadez J.G., Grover V.K., Carter M.D., Calcutt M.W., Abiria S.A., Lundberg C.J., et al. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. Cancer Letters 2013, 328(2):297-306.
298. Van den Bent M.J., Dubbink H.J., Marie Y., Brandes A.A., Taphoorn M.J.B., Wesseling P., et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16(5):1597-1604. 10.1158/1078-0432.CCR-09-2902.
299. Van den Boom J., Wolter M., Kuick R., Misek D.E., Youkilis A.S., Wechsler D.S., et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. The American Journal of Pathology 2003, 163(3):1033-1043.
300. Venneti S., Garimella M.T., Sullivan L.M., Martinez D., Huse J.T., Heguy A., et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathology 2013, 23:558-564.
301. Verhaak R.G.W., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110. 10.1016/j.ccr.2009.12.020.
302. Vivanco I., Robins H.I., Rohle D., Campos C., Grommes C., Nghiemphu P.L., et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery 2012, 2(5):458-471. 10.1158/2159-8290.CD-11-0284.
303. Vlassenko A.G., Thiessen B., Beattie B.J., Malkin M.G., Blasberg R.G. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. Journal of Neuro-Oncology 2000, 46(3):249-259. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/10902856.
304. Wachsberger P.R., Lawrence R.Y., Liu Y., Xia X., Andersen B., Dicker A.P. Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: Implications for the clinic. Journal of Neuro-Oncology 2011, 105(2):181-190. 10.1007/s11060-011-0580-y.
305. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833. 10.1038/nature09624.
306. Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackleford G.M., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research 2006, 66(16):7864-7869. 10.1158/0008-5472.CAN-04-4392.
307. Wang J., O'Bara M.A., Pol S.U., Sim F.J. CD133/CD140a-based isolation of distinct human multipotent neural progenitor cells and oligodendrocyte progenitor cells. Stem Cells and Development 2013, 22(15):2121-2131. 10.1089/scd.2013.0003.
308. Wang S., Sdrulla A.D., diSibio G., Bush G., Nofziger D., Hicks C., et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 1998, 21:63-75. Retrieved from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9697852.
309. Wang Q., Wei F., Li C., Lv G., Wang G., Liu T., et al. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma. PloS One 2013, 8(8):e73175. 10.1371/journal.pone.0073175.
310. Wang Y., Yang J., Zheng H., Tomasek G.J., Zhang P., McKeever P.E., et al. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 2009, 15:514-526. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/19477430.
311. Wang T.-W., Zhang H., Gyetko M.R., Parent J.M. Hepatocyte growth factor acts as a mitogen and chemoattractant for postnatal subventricular zone-olfactory bulb neurogenesis. Molecular and Cellular Neurosciences 2011, 48:38-50. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3160177&tool=pmcentrez&rendertype=abstract.
312. Watanabe T., Nobusawa S., Kleihues P., Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. The American Journal of Pathology 2009, 174(4):1149-1153.
313. Waters J.D., Sanchez C., Sahin A., Futalan D., Gonda D.D., Scheer J.K., et al. CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. Journal of Neuro-Oncology 2012, 110(1):37-48. 10.1007/s11060-012-0948-7.
314. Wei Q., Clarke L., Scheidenhelm D.K., Qian B., Tong A., Sabha N., et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Research 2006, 66:7429-7437. Retrieved from. http://www.ncbi.nlm.nih.gov/pubmed/16885338.
315. Weiss W.A., Burns M.J., Hackett C., Aldape K., Hill J.R., Kuriyama H., et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Research 2003, 63:1589-1595. http://www.ncbi.nlm.nih.gov/pubmed/12670909.
316. Weiss S., Dunne C., Hewson J., Wohl C., Wheatley M., Peterson A.C., et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 1996, 16(23):7599-7609.
317. Wilkinson G., Dennis D., Schuurmans C. Proneural genes in neocortical development. Neuroscience 2013, 253C:256-273.
318. Wu G., Broniscer A., McEachron T.A., Lu C., Paugh B.S., Becksfort J., et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genetics 2012, 44(3):251-253.
319. Xu Y., Tamamaki N., Noda T., Kimura K., Itokazu Y., Matsumoto N., et al. Neurogenesis in the ependymal layer of the adult rat 3rd ventricle. Experimental Neurology 2005, 192(2):251-264.
320. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 219(1):17-30.
321. Yakes F.M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular Cancer Therapeutics 2011, 10(12):2298-2308. 10.1158/1535-7163.MCT-11-0264.
322. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 2009, 360(8):765-773.
323. Yang R.Y.C., Yang K.S., Pike L.J., Marshall G.R. Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors. Chemical Biology & Drug Design 2010, 76(1):1-9. 10.1111/j.1747-0285.2010.00986.x.
324. Yip S., Butterfield Y.S., Morozova O., Chittaranjan S., Blough M.D., An J., et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. The Journal of Pathology 2011, 226(1):7-16.
325. Yu D., Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: In vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 2002, 21(12):1922-1927.
326. Zhang Hongbing, Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. The Journal of Clinical Investigation 2007, 117(3):730-738. 10.1172/JCI28984.
327. Zhang H., Liu C.-Y., Zha Z.-Y., Zhao B., Yao J., Zhao S., et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. The Journal of Biological Chemistry 2009, 284(20):13355-13362.
328. Zhang J., Wu G., Miller C.P., Tatevossian R.G., Dalton J.D., Tang B., et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genetics 2013, 45(6):602-612.
329. Zhao B., Li L., Lei Q., Guan K.-L. The Hippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes & Development 2010, 24(9):862-874.
330. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324(5924):261-265.
331. Zheng H., Ying H., Yan H., Kimmelman A.C., Hiller D.J., Chen A.J., et al. Nature. 2008, 455(7216):1129-1133. 10.1038/nature07443.
332. Zhu Y., Guignard F., Zhao D., Liu L., Burns D.K., Mason R.P., et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005, 8:119-130. Retrieved from. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3024718&tool=pmcentrez&rendertype=abstract.
333. Zuo H., Nishiyama A. Polydendrocytes in development and myelin repair. Neuroscience Bulletin 2013, 1-12. 10.1007/s12264-013-1320-4.